| One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
|
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
| Current and emerging strategies for management of myelodysplastic syndromes |
|
Blood reviews |
Myelodysplastic Syndromes (MDS) |
| Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
|
Seminars in Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
